Table 2.
Study outcomes
| Sham-RIPC (n = 43) | RIPC (n = 41) | P | |
|---|---|---|---|
| Peak hsTNT, n (%) | 0.327 | ||
| < 5 ng/L | 8 (19%) | 13 (31%) | |
| 5–14 ng/L | 26 (60%) | 19 (46%) | |
| > 14 ng/L | 9 (21%) | 9 (22%) | |
| Mean peak hsTNT (ng/L) | |||
| All | 10.3 (5.6, 13.7) | 7.8 (4.4, 12.9) | 0.397 |
| PMI (> 14 ng/L) | 17.1 (16.5, 29.0) | 20.5 (17.0, 35.0) | 0.387 |
| PMI (> 5 ng/L) | 11.5 (8.8, 15.6) | 7.7 (5.7, 11.0) | 0.973 |
| hsTnT AUC to 72 h | |||
| All | 394 (202, 527) | 335 (130, 660) | 0.700 |
| PMI (> 14 ng/L) | 868 (559, 1256) | 816 (410, 1050) | 0.711 |
| PMI (> 5 ng/L) | 481 (286, 669) | 481 (320, 810) | 0.548 |
| Secondary outcomes | |||
| MACCE to 1 year | 4 (9%) | 1 (2%) | 0.36 |
| Surgical complication | 11 (26%) | 8 (20%) | 0.605 |
| Length of stay | 6 (4, 9) | 5 (3, 8.5) | 0.472 |
| Sympathomimetic use | 32 (80%) | 27 (73%) | 0.592 |
| Venous lactate (mmol/L) | 1.5 (1.0, 2.1) | 1.2 (0.9, 1.75) | 0.288 |
| Venous creatinine (μmol/L) | 78 (67, 96) | 76 (64, 101) | 0.666 |
Descriptives are count (percentage) and compared with chi squared tests, or median (25th percentile, 75th percentile) and compared with Mann-Whitney U test. MACCE major adverse cardiac and cerebrovascular events